Hair loss can be frustrating, especially when you are looking for a treatment that is effective, convenient, and medically sound. TH07 is one of the newest investigational hair loss treatments attracting global attention because it combines three active ingredients into a single topical formula for androgenetic alopecia, also known as male pattern hair loss.
At Derma Clinic, we believe it is important to separate early internet excitement from real clinical evidence like Clascoterone, PP404. TH07 is highly promising, but it is still under development and has not yet been approved for routine commercial use. Here is a medically grounded look at what TH07 is and what the data reveals.
What Is TH07?
TH07 is a prescription topical treatment being developed by the Canadian biotechnology company Triple Hair Inc. for androgenetic alopecia in men. Instead of relying on a single pathway, it combines minoxidil 5%, finasteride 0.1%, and latanoprost 0.03% into one standardized formulation.
TH07 Ingredients and Their Roles
| Ingredient | Main Role | Why It Matters |
| Minoxidil 5% | Supports hair growth | One of the most established topical treatments for stimulating follicles. |
| Finasteride 0.1% | Helps reduce DHT-related shrinkage | Targets one of the main hormonal causes of male pattern hair loss. |
| Latanoprost 0.03% | May stimulate the active growth phase | A newer prostaglandin analogue showing early promise in hair restoration. |
Each ingredient targets hair loss differently, which is why the combination is generating such strong interest in the dermatology community.
How Does TH07 Work?
Androgenetic alopecia happens when hair follicles gradually become smaller (miniaturize) due to genetic and hormonal factors, especially dihydrotestosterone, or DHT. TH07 is designed to work on multiple pathways at the same time:
- Minoxidil: A well-established vasodilator that helps support follicle activity and hair regrowth by improving blood flow to the scalp.
- Finasteride: Works by reducing the local effects of DHT on the scalp, blocking the major hormone involved in pattern hair loss.
- Latanoprost: A prostaglandin analogue that has shown potential in helping hair follicles remain in or return to the active growth (anagen) phase.
What Does the Research Show?
The most relevant evidence for TH07 comes from a recently published Phase II proof-of-concept pilot study in the International Journal of Trichology. The study reported better hair regrowth with the triple-combination formula than with the individual ingredients used alone. In the trial, over 82% of participants using TH07 experienced positive results.
Evidence Summary
| Finding | What It Suggests | Important Limitation |
| Better regrowth than single ingredients | TH07 may work synergistically and better as a combination. | The Phase II study was small and early-stage. |
| Good tolerance in early study | Topical use may reduce systemic concerns. | Longer safety data across a broader population is still needed. |
| Encouraging early outcomes | TH07 is a promising future option. | It is not yet proven at the same level as approved standard treatments. |
Important Point: TH07 has successfully shown proof-of-concept, but it is currently undergoing larger trials to rigorously test its long-term safety and efficacy.
Is TH07 Approved?
No, TH07 is not yet commercially available for routine prescription use.
Development Status
| Status | Current Situation |
| Regulatory Status | Not yet approved for general market use. |
| Clinical Stage | Under Phase III clinical evaluation. |
| Availability | Not currently available as a standard treatment. |
| Outlook | Future availability depends on trial results and regulatory review. |
Triple Hair Inc. recently hit a major milestone: as of April 2026, the first patient was officially dosed in their pivotal Phase III clinical trials in Canada. This 24-week study will involve 420 men, marking an important step forward. However, the treatment still has a comprehensive regulatory path ahead before it can become widely available.
Possible Side Effects
Because TH07 is a topical application rather than an oral pill, it significantly reduces systemic exposure to the active ingredients—particularly finasteride. That is one reason it is attracting so much clinical interest.
Possible Side Effects
| Type of Side Effect | Examples |
| Local Side Effects | Scalp irritation, dryness, itching, or redness at the application site. |
| Systemic Concerns | Systemic absorption is drastically reduced compared to oral finasteride, and no sexual dysfunction was reported in Phase II. However, long-term Phase III data is still needed. |
As with any prescription hair loss treatment, patients should speak with a qualified dermatologist before starting therapy.
TH07 vs. Standard Hair Loss Treatments
TH07 is based on ingredients already used in hair loss care, but the novelty lies in combining them into one standardized topical formula.
Comparison with Common Treatments
| Treatment | Mechanism | FDA Approved | Application | Side Effects | Best For | Availability |
|---|---|---|---|---|---|---|
| TH07 | Triple: Minoxidil (growth) + Finasteride (DHT block) + Latanoprost (follicle stim) | No (Phase III) | Topical daily | Local irritation (low systemic risk) | Moderate AGA, multi-pathway needs | Clinical trials (2+ yrs) |
| Minoxidil 5% | Vasodilation + growth factor stim | Yes (1979) | Topical 2x daily | Shedding, scalp itch (5-10%) | Early crown thinning | Immediate (OTC) |
| Finasteride 1mg | 5α-reductase inhibitor (DHT ↓65%) | Yes (1997) | Oral daily | Sexual side effects (2-4%) | Vertex + frontal loss | Immediate (Rx) |
| Dutasteride 0.5mg | Dual 5α-reductase (DHT ↓90%) | No (off-label) | Oral daily | Higher sexual risk (5-8%) | Advanced AGA | Immediate (Rx) |
Who May Benefit in the Future?
If TH07 is eventually approved, it may be a highly useful option for men with androgenetic alopecia who want a single, topical application that attacks hair loss through multiple mechanisms. It will be particularly interesting to patients who prefer to minimize oral medication exposure while still effectively addressing DHT-related hair loss.
Dermatologist’s Advice for Managing Hair Loss Today
The absolute best results in hair loss treatment come from early diagnosis and early intervention.
When to See a Dermatologist
| Situation | Why It Matters |
| Sudden hair shedding | May indicate a different underlying medical cause than pattern hair loss. |
| Receding hairline | Early treatment is the most effective way to preserve existing hair. |
| Thinning at the crown | A hallmark early sign of androgenetic alopecia. |
| Family history of hair loss | Greatly increases your genetic predisposition for pattern hair loss. |
| Failed OTC treatments | You likely need a stronger, prescription-based, or procedural medical plan. |
At Derma Clinic, we recommend a personalized approach based on your specific type of hair loss, age, degree of shedding, medical history, and treatment goals.
Check out our aricle on Blood Test for Hair Loss
Emerging Hair Loss Treatments: Clascoterone, PP405 vs TH07
While TH07 represents a multi-mechanism combination approach targeting androgenetic alopecia through vasodilation (minoxidil), DHT blockade (finasteride), and follicle stimulation (latanoprost), it differs fundamentally from two other promising investigational treatments: Clascoterone 5% (Breezula) and PP405.
Clascoterone works as a topical androgen receptor inhibitor that “shields” follicles from DHT effects locally without systemic absorption, making it particularly valuable for preventing further loss in early-to-moderate male pattern baldness (Norwood 2-4) where hormonal protection is the priority.
PP405, conversely, employs a novel metabolic approach by inhibiting the mitochondrial pyruvate carrier to “wake up” dormant stem cells through lactate production, offering potential true regeneration for miniaturized follicles in both men and women.
TH07’s combination strategy likely excels for comprehensive management of moderate progression where multiple pathways need addressing simultaneously, but Clascoterone may suit hormone-focused prevention better, while PP405 targets stem cell reactivation in more advanced cases—all three underscoring the shift toward targeted, topical alternatives to oral finasteride with minimal systemic risk.
Learn more: Clascoterone vs PP405 vs Finasteride | PP405 Hair Restoration
Stop Hair Fall Now: Best Treatments While Awaiting TH07
For men asking “how to stop hair fall immediately”, start minoxidil 5% twice daily (FDA-approved, available at pharmacies) combined with finasteride 1mg through dermatologist prescription—the best evidence-based treatment for androgenetic alopecia today. Natural regrowth like rosemary oil or scalp massage shows modest results (10-20% improvement vs 60-80% medical), but medical treatments work 3-4x faster with proven follicle preservation. At Derma Clinic Kathmandu, we combine these with GFC/PRP therapy for optimal results while patients await TH07’s Phase III completion (2+ years). Don’t lose more follicles—start comprehensive treatment today.
FAQs
What ingredients are in TH07?
TH07 combines three active ingredients: minoxidil 5% (promotes hair growth), topical finasteride 0.1% (blocks DHT), and latanoprost 0.03% (stimulates follicle activity). This triple-action formula targets androgenetic alopecia through multiple biological pathways simultaneously.
When will TH07 be available?
TH07 is currently in Phase III clinical trials and is not yet available for routine prescription use. Triple Hair announced the first patient dosing in April 2026. After completing these larger trials (expected 24 weeks), regulatory approval could take 1-2 additional years.
Is TH07 FDA approved?
No, TH07 is investigational and not yet approved by any regulatory authority including FDA, Health Canada, or EMA. Phase III results are needed before regulatory submission, making widespread availability several years away.
Can women use TH07?
TH07 is currently being developed specifically for male androgenetic alopecia. The Phase III trials target men only. Women should consult a dermatologist about appropriate treatments like topical minoxidil 2-5% or other female-pattern hair loss options.
How does TH07 compare to minoxidil alone?
Early Phase II data suggests the TH07 triple combination produces better hair regrowth than minoxidil used alone. The small study showed 82% positive response rate vs individual ingredient results, though larger Phase III trials are needed for confirmation.
Does TH07 have fewer side effects than oral finasteride?
Topical finasteride 0.1% in TH07 has significantly lower systemic absorption than oral finasteride 1mg. Early studies reported no systemic side effects like sexual dysfunction, though local scalp irritation remains possible with any topical treatment.
What is the cost of TH07 treatment?
Pricing has not been announced since TH07 remains in clinical development. As a prescription combination containing latanoprost (historically expensive), expect premium pricing above standard minoxidil products when available.
How long does TH07 take to work?
Early study participants saw visible improvement after 3-6 months of daily use. Like all hair loss treatments, TH07 requires consistent application and results continue improving through 12 months. Hair shedding may temporarily increase during the first 1-2 months.
Can TH07 reverse a receding hairline?
TH07 shows promise for crown thinning but frontal hairline regrowth is more challenging. Early data focused primarily on vertex (crown) improvement. Complete reversal of advanced Norwood stage recession remains unlikely with any current treatment.
Is TH07 better than PRP hair treatment?
No direct comparison studies exist between TH07 and PRP (platelet-rich plasma). TH07 targets DHT blocking and follicle stimulation pharmacologically, while PRP uses growth factors from the patient’s blood. Both may work better combined than alone.
Will my hair loss return if I stop TH07?
Yes, like all medical hair loss treatments, results require ongoing use. TH07 does not cure the genetic sensitivity causing androgenetic alopecia. Hair regrowth is typically lost within 6-12 months of discontinuation, similar to minoxidil and finasteride.
Can I use TH07 with other hair loss treatments?
TH07 already combines three mechanisms, reducing the need for additional topicals. Adding microneedling, low-level laser therapy, or oral supplements may provide additive benefit. Always consult a dermatologist before combining treatments to avoid interactions.
What does Phase III mean for TH07?
Phase III trials test TH07 in hundreds of patients (420 planned) over 24 weeks to confirm safety and efficacy at scale. This is the final major step before regulatory approval. Positive results could lead to market authorization within 2 years.
Is latanoprost safe for scalp use?
Latanoprost 0.03% is well-tolerated topically at hair loss concentrations. Originally an FDA-approved glaucoma eye drop, scalp application shows minimal systemic absorption. Eye irritation was not reported in TH07 studies when used as directed.
Should I wait for TH07 or start treatment now?
Don’t wait if hair loss is progressing—early intervention preserves more follicles. Proven treatments like topical minoxidil, finasteride, or clinic procedures are available immediately at Derma Clinic. TH07 remains years from routine availability.
Final Thoughts
TH07 is an exciting investigational treatment for male pattern hair loss because it combines minoxidil, finasteride, and latanoprost in one multi-targeted topical formula. Early results are highly encouraging, but the treatment is still under clinical evaluation and is not yet available for routine use.
If you are noticing thinning hair, do not wait for the “next big treatment” to arrive. Preserving the hair you have is much easier than regrowing what is gone. Book a consultation with us at Derma Clinic in Kathmandu today so we can thoroughly assess your hair loss and create a comprehensive treatment plan based on proven, currently available evidence.
References
- TH07 – A New Novel Topical Treatment for Androgenic Alopecia. International Journal of Trichology. https://pmc.ncbi.nlm.nih.gov/articles/PMC11588191/
- Triple Hair Doses First Patient in Phase III Clinical Trial in Canada for Male Androgenic Alopecia. https://www.businesswire.com/news/home/20260402104876/en/Triple-Hair-Doses-First-Patient-in-Phase-III-Clinical-Trial-in-Canada-f
- Guidelines based management of androgenetic alopecia. https://cosmoderma.org/guidelines-based-management-of-androgenetic-alopecia/
- Triple Hair Clinical Study Featured in Peer-Reviewed Scientific Journal. https://triplehair.ca/th07-clinical-study-featured-in-peer-reviewed-journal/
- Triple Hair Group receives Health Canada approval to start Phase III clinical trials on Therapy-07. https://triplehair.ca/triple-hair-group-receives-health-canada-approval-to-start-phase-iii-clinical-trials-on-its-therapy-07-pre/